Interleukin-10 reduces scar formation in both animal and human cutaneous wounds: Results of two preclinical and phase II randomized control studies

Wound Repair and Regeneration

Volumn 21, Issue 3, 2013, Pages 428-436

  Kieran, Ingrid ^a   Knock, Amanda ^a   Bush, James ^a   So, Karen ^a   Metcalfe, Anthony ^a   Hobson, Rosalind ^a   Mason, Tracey ^a   O'Kane, Sharon ^a   Ferguson, Mark ^a  

^a Renovo Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 4; PLACEBO;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SCAR FORMATION; SKIN INJURY; WILD TYPE; WOUND HEALING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CICATRIX; DISEASE MODELS, ANIMAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-10; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; RATS; RATS, SPRAGUE-DAWLEY; SKIN; TREATMENT OUTCOME; WOUND HEALING; WOUNDS AND INJURIES; YOUNG ADULT;

EID: 84877579106     PISSN: 10671927     EISSN: 1524475X     Source Type: Journal    
DOI: 10.1111/wrr.12043     Document Type: Article

References (25)

1. Hurst J, Siciliani L,. Tackling excessive waiting times for elective surgery: a comparison of policies in twelve OECD countries. OECD Health Working Papers. 2003. Available at http://www.oecd.org (accessed March 30, 2013).
2. Bayat A, McGrouther DA, Ferguson MW,. Skin scarring. BMJ 2003; 326: 88-92.
3. Fiorentino DF, Bond MW, Mosmann TR,. Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989; 170: 2081-2095.
4. Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM,. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 151: 1224-1234.
5. De Vries JE, de Waal Malefyt R,. Interleukin-10. New York: Springer-Verlag, 1995: chap 5.
6. Reitamo S, Remitz A, Tamai K, Uitto J,. Interleukin-10 modulates type I collagen and matrix metalloprotease gene expression in cultured human skin fibroblasts. J Clin Invest 1994; 94: 2489-2492.
7. Liechty KW, Adzick NS, Crombleholme TM,. Diminished interleukin 6 (IL-6) production during scarless human fetal wound repair. Cytokine 2000; 12: 671-676.
8. Nelson DR, Lauwers GY, Lau JY, Davis GL,. Interleukin-10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology 2000; 118: 655-660.
9. Friedrich M, Docke WD, Klein A, Philipp S, Volk HD, Sterry W, Asadullah K,. Immunomodulation by interleukin-10 therapy decreases the incidence of relapse and prolongs the relapse-free interval in psoriasis. J Invest Dermatol 2002; 118: 672-677.
10. Arai T, Abe K, Matsuoka H, Yoshida M, Mori M, Goya S, et al. Introduction of the interleukin-10 gene into mice inhibited bleomycin-induced lung injury in vivo. Am J Physiol Lung Cell Mol Physiol 2000; 278: 914-922.
11. Zhang N, Cui HD, Xue HX,. Effect of local viral transfer of interleukin-10 gene on a rabbit arthritis model induced by interleukin 1beta. Chin Med J (Engl) 2008; 121: 435-438.
12. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-e24.
13. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W,. Interleukin-10- deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274.
14. Berg DJ, Davidson N, Kühn R, Muller W, Menon S, Holland G, et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest 1996; 98: 1010-1020.
15. Kuhn JR, Rajewsky K, Muller W,. Generation and analysis of interleukin-4 deficient mice. Science 1991; 254: 707-710.
16. Duncan JA, Bond JS, Mason T, Ludlow A, Cridland P, O'Kane S, et al. Visual analogue scale scoring and ranking: a suitable and sensitive method for assessing scar quality? Plast Reconstr Surg 2006; 118: 909-918.
17. Ferguson MW, Duncan J, Bond J, Bush J, Durani P, So K, et al. Prophylactic administration of avotermin for improvement of skin scarring: three double-blind, placebo-controlled, phase I/II studies. Lancet 2009; 373: 1264-1274.
18. Armstrong JR, Ferguson MW,. Ontogeny of the skin and the transition from scar-free to scarring phenotype during wound healing in the pouch young of a marsupial, Monodelphis domestica. Dev Biol 1995; 169: 242-260.
19. Whitby DJ, Ferguson MW,. The extracellular matrix of lip wounds in fetal, neonatal and adult mice. Development 1991; 112: 651-668.
20. Longaker MT, Whitby DJ, Adzick NS, Crombleholme TM, Langer JC, Duncan BW, et al. Studies in fetal wound healing, VI. Second and early third trimester fetal wounds demonstrate rapid collagen deposition without scar formation. J Pediatr Surg 1990; 25: 63-68.
21. Shah M, Revis D, Herrick S, Baillie R, Thorgeirson S, Ferguson M, et al. Role of elevated plasma transforming growth factor-beta1 levels in wound healing. Am J Pathol 1999; 154: 1115-1124.
22. So K, McGrouther DA, Bush JA, Durani P, Taylor L, Skotny G, et al. Avotermin for scar improvement following scar revision surgery: a randomized, double-blind, within-patient, placebo-controlled, phase II clinical trial. Plast Reconstr Surg 2011; 128: 163-172.
23. Bush JA, McGrouther DA, Young VL, Herndon DN, Longaker MT, Mustoe TA, et al. Recommendations on clinical proof of efficacy for potential scar prevention and reduction therapies. Wound Repair Regen 2011; 19 (Suppl. 1): s32-37.
24. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Narula SK, Smith SR, Roncarolo MG, et al. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versus-host disease. Transplantation 1998; 66: 1220-1229.
25. Taylor C,. Scar maturation in the African Continental Ancestry Group. University of Manchester, unpublished material. 2013.